Vazirani Asset Management LLC Has $41,000 Stake in Ikena Oncology, Inc. (NASDAQ:IKNA)

Vazirani Asset Management LLC decreased its stake in Ikena Oncology, Inc. (NASDAQ:IKNA) by 78.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,000 shares of the company’s stock after selling 90,668 shares during the period. Ikena Oncology accounts for approximately 0.1% of Vazirani Asset Management LLC’s holdings, making the stock its 18th largest position. Vazirani Asset Management LLC’s holdings in Ikena Oncology were worth $41,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. JPMorgan Chase & Co. grew its stake in Ikena Oncology by 18,244.1% during the fourth quarter. JPMorgan Chase & Co. now owns 155,741 shares of the company’s stock worth $255,000 after buying an additional 154,892 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Ikena Oncology by 5.6% in the 3rd quarter. Geode Capital Management LLC now owns 271,026 shares of the company’s stock worth $469,000 after acquiring an additional 14,319 shares during the last quarter. Peapod Lane Capital LLC purchased a new stake in Ikena Oncology during the fourth quarter worth about $833,000. Gilead Sciences Inc. bought a new position in shares of Ikena Oncology during the 4th quarter worth $3,294,000. Finally, BML Capital Management LLC lifted its position in shares of Ikena Oncology by 395.8% during the fourth quarter. BML Capital Management LLC now owns 3,585,866 shares of the company’s stock worth $5,881,000 after acquiring an additional 2,862,578 shares in the last quarter. 75.00% of the stock is currently owned by institutional investors.

Ikena Oncology Stock Performance

Ikena Oncology stock opened at $1.19 on Monday. The stock has a market cap of $57.43 million, a P/E ratio of -0.97 and a beta of 0.48. The firm’s fifty day moving average price is $1.27 and its 200-day moving average price is $1.50. Ikena Oncology, Inc. has a fifty-two week low of $0.97 and a fifty-two week high of $1.94.

Ikena Oncology (NASDAQ:IKNA) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05. On average, analysts predict that Ikena Oncology, Inc. will post -0.91 earnings per share for the current year.

Ikena Oncology Company Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.